Developed by the Russian Scientific Medical Society of Internal Medicine, Scientific Society of Gastroenterologists of Russia, National Society of Preventive Cardiology, 2021
MEMBERS OF THE WORKING GROUP:
Kochetkov A.I., PhD, associate professor (Moscow), Ostroumova O.D., MD, professor (Moscow), Pereverzev A.P., PhD, associate professor (Moscow)
MEMBERS OF THE EXPERT COUNCIL:
Martynov A.I., MD, professor, academician of RAS (Moscow), Bakulin I.G., MD, professor (Saint Petersburg), Vertkin A.L., MD, professor (Moscow), Drozdov V.N., MD, professor (Moscow), Zyryanov S.K., MD, professor (Moscow), Kislyak O.A., MD, professor (Moscow), Lazebnik L.B., MD, professor (Moscow), Loranskaya I.D., MD, professor (Moscow), Ostroumova O.D., MD, professor (Moscow), Pogosova N.V., MD, professor (Moscow), Sychev D.A., MD, professor, corresponding member of RAS (Moscow), Shikh E.V., MD, professor (Moscow)
Key words: direct oral anticoagulants, vitamin K antagonists, gastrointestinal bleeding, proton-pump inhibitors, rebamipide.
The authors declare no conflict of interests.
For citation: Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants.
Therapy. 2021; 10: 23–41.
Doi: https://dx.doi.org/10.18565/therapy.2021.10.23–41